Core Viewpoint - The southbound capital has increased its holdings in Yipai Sunshine (02522.HK) significantly, indicating strong investor interest and confidence in the company's performance [1]. Group 1: Shareholding Changes - On October 22, 2025, southbound capital increased its holdings by 117,500 shares, bringing the total to 128 million shares, which represents 43.35% of the company's issued ordinary shares [1][2]. - Over the past five trading days, there have been four days of net increases, totaling 861,500 shares [1]. - In the last 20 trading days, there were 10 days of net increases, amounting to 1,119,500 shares [1]. Group 2: Company Overview - Jiangxi Yipai Sunshine Group Co., Ltd. primarily engages in specialized medical imaging services in China [2]. - The company operates three segments: imaging center services, imaging solutions, and Yipai cloud services [2]. - Imaging center services provide diagnostic imaging services through flagship imaging centers, while imaging solutions assist healthcare institutions in selecting and procuring suitable imaging equipment [2].

Core Viewpoint - The launch of the AIR product by Yipai Yangguang marks a significant milestone in the medical imaging AI sector, transitioning from the 1.0 era of single-disease models to the 2.0 era driven by large foundational models, enhancing diagnostic capabilities across multiple organs and diseases [4] Company Summary - Yipai Yangguang, the largest third-party medical imaging center operator in China, experienced a stock price increase of over 7.1% initially, settling at a 1.91% rise to HKD 16.53 per share [3] - The AIR product, developed by the AI company Yinghe Yimai, is the first commercial outcome of the foundational model ecosystem, capable of simultaneous detection and diagnosis of multiple organs in a single chest CT scan [4] - The company aims to leverage its resources in medical imaging data and scenarios to enhance the performance of the foundational model and expand AI diagnostic products [4][5] Industry Summary - The third-party medical imaging service sector is recognized for its significant growth potential, supported by government policies encouraging the development of independent medical imaging centers [5] - The AI + medical imaging market in China is projected to exceed RMB 90 billion by 2025, with a compound annual growth rate (CAGR) of 58.3% from 2020 to 2025, significantly outpacing the global average [5] - The introduction of the AIR product is expected to strengthen Yipai Yangguang's core competitiveness in imaging center services, providing new momentum for the company's growth [5]

Market Overview - The Hang Seng Index fell by 1.61%, down 415 points, closing at 25,472 points, while the Hang Seng Tech Index dropped by 2.81%. The early trading volume in the Hong Kong market was HKD 153.2 billion [1] Energy Sector - Gas stocks rose, with Zhongyu Energy (03633) increasing by over 10%. This surge is attributed to the early initiation of winter heating in Gansu and other regions due to continuous temperature drops, leading to increased natural gas demand [1] Biotechnology Sector - Newly listed stock Xuan Zhu Bio-B (02575) surged over 13%, reaching a new high, and is up more than 190% from its IPO price. Yimai Sunshine (02522) rose over 4% following the global launch of its medical imaging model product AIR. The performance of medical stocks varied, with Yaojie Ankang-B (02617.HK) up over 21%, Baize Medical (02609) up over 5%, while Kangfang Biotech (09926) fell by 2%. Kangning Jereh Pharma-B (09966) increased by over 13% after announcing a share buyback plan, with market attention on significant data from the ESMO conference [2] Precious Metals Sector - Laopu Gold (06181) rose over 4%, benefiting from increased channel expansion and upgrades, with institutions indicating that rising gold prices favor its high-end brand positioning [3] Hospitality Sector - Wanda Hotel Development (00169) increased by over 10% after completing a sale and announcing a special dividend of HKD 0.462 per share to be paid next month [4] Digital Assets Sector - Delin Holdings (01709) rose over 3% after entering a strategic cooperation agreement with Antalpha to promote business in the digital asset sector [5] Telecommunications Sector - Changfei Optical Fiber and Cable (06869) fell over 6%, having dropped 40% from its September peak due to declining fiber optic prices and shareholder sell-offs. Cryptocurrency-related stocks collectively declined, with Bitcoin experiencing significant volatility and a recent incident in the US stablecoin market. Mi Strategy (02440) fell by 4.36%, and OSL Group (00863) dropped by 3.99% [6] Semiconductor Sector - Chip stocks continued to decline, with SMIC (00981) down over 5% and Huahong (01347) down over 3%, as US export controls accelerate domestic semiconductor replacements [6]

Group 1 - The stock of Yipai Yangguang (02522.HK) rose over 6% in early trading, reaching an increase of 6.23% at a price of 17.23 HKD [1] - The trading volume amounted to 80.63 million HKD [1]

Core Viewpoint - The announcement of the AIR product by Yimai Sunshine marks a significant advancement in the field of medical imaging AI, transitioning from the 1.0 era of single-disease small models to the 2.0 era driven by a foundational large model, showcasing comprehensive diagnostic capabilities across multiple organs [1][2] Group 1 - Yimai Sunshine's stock rose over 6%, reaching HKD 17.23 with a trading volume of HKD 80.63 million following the announcement of the AIR product [1] - The AIR product is the first commercial outcome of the Yimai Medical's foundational large model ecosystem, designed to connect top hospitals with grassroots medical institutions through open interfaces [2] - The AIR product focuses on chest CT scans, enabling simultaneous detection and diagnosis of all common diseases in the lungs, pleura, and mediastinum from a single scan [1] Group 2 - The AIR product is expected to significantly shorten the AI product development cycle and reduce costs, facilitating standardized screening, intelligent diagnosis, and inclusive services in medical institutions [2] - The model promotes a positive feedback loop of "data-model-scenario" that enhances collaboration across the industry chain [2] - The technology behind the AIR product emphasizes efficient diagnosis, precise coverage, interactive collaboration, and seamless integration, fundamentally reconstructing the logic of medical imaging AI development and application [1]

Core Viewpoint - The announcement of the AIR product by Yimai Sunshine marks a significant advancement in the field of medical imaging AI, transitioning from the 1.0 era of single disease small models to the 2.0 era driven by foundational large models, showcasing a milestone breakthrough in intelligent diagnosis [1][2] Group 1: Product Launch and Features - Yimai Sunshine's AIR product, developed by its incubated AI company Shanghai Yinghe Medical Technology, is the world's first AI-assisted diagnostic product based on a large medical imaging model [1] - The AIR product focuses on chest CT scans, enabling comprehensive detection and diagnosis of all common diseases in the lungs, pleura, and mediastinum with a single scan [1] - The product is built on the "Yinghe Mijia" model, which features multi-organ collaborative diagnosis capabilities, fundamentally restructuring the development and application logic of medical imaging AI [1] Group 2: Ecosystem and Market Impact - The AIR product serves as the first commercial outcome of the Yinghe Medical's foundational large model ecosystem, connecting top hospitals with grassroots medical institutions through open interfaces [2] - This model aims to create a positive cycle of "data feeding back model iteration, model driving scene implementation," significantly shortening AI product development cycles and reducing costs [2] - The initiative is expected to enhance screening standards, promote intelligent diagnosis, and facilitate inclusive services within the healthcare industry, effectively driving industry chain collaboration and establishing a "data-model-scene" closed-loop ecosystem [2]

Core Insights - The company Yimai Sunshine (02522) announced the launch of the world's first AI-assisted diagnostic product, AIR, developed by its affiliated AI company, Shanghai Yinghe Medical Technology Co., Ltd. This product marks a significant advancement in medical imaging AI, transitioning from the "single disease small model" era to the "foundation model-driven" era, showcasing capabilities for comprehensive diagnosis across multiple organs and diseases [1][2] Group 1 - The AIR product focuses on chest CT scans, enabling simultaneous detection and diagnosis of all common diseases in the lungs, pleura, and mediastinum with a single scan [1] - AIR is based on the world's first cross-modal, full-process medical imaging foundation model, "Yinghe Mijia," which enhances diagnostic efficiency, precision, and seamless integration [1][2] - The launch of AIR signifies a shift from "single-point breakthroughs" to "systematic empowerment" in medical imaging AI, transforming the industry from "single disease detection" to "multi-disease collaborative analysis" [2] Group 2 - AIR serves as the first commercial outcome of the Yinghe Medical foundation model ecosystem, connecting top hospitals with grassroots medical institutions to create a positive feedback loop for data-driven model iteration and scene implementation [2] - This model is expected to significantly shorten AI product development cycles, reduce costs, and promote standardized screening, intelligent diagnosis, and inclusive services across the healthcare industry [2] - The technological innovation of "one scan, multiple disease simultaneous diagnosis" is anticipated to enhance the competitiveness and added value of the company's imaging center services [2]

Core Insights - The company Yimai Sunshine (02522.HK) announced the launch of the world's first AI-assisted diagnostic product for chest CT scans, named AIR, developed by its incubated AI company Shanghai Yinghe Yimai Intelligent Technology Co., Ltd. This marks a significant advancement in medical imaging AI from the "single disease small model" era to the "foundation large model-driven" era [1][2] Group 1 - The AIR product is designed to perform comprehensive diagnostics across multiple organs, focusing initially on chest CT scans, enabling simultaneous detection and diagnosis of conditions in the lungs, pleura, and mediastinum [1] - The product is based on the world's first cross-modal, full-process medical imaging foundation large model, "Yinghe Mijia," showcasing its capabilities in multi-organ collaborative diagnosis and efficient integration [1][2] - The launch of the AIR product signifies a shift in medical imaging AI from "point breakthroughs" to "systematic empowerment," transforming the role of AI from a diagnostic tool to a diagnostic partner [2] Group 2 - The AIR product facilitates a positive feedback loop by connecting top hospitals with grassroots medical institutions through open interfaces, which will shorten AI product development cycles and reduce costs [2] - This model aims to standardize screening, enhance diagnostic intelligence, and promote inclusive services, thereby driving collaboration across the industry and establishing a closed-loop ecosystem of "data-model-scenario" [2] - The technological innovation of "one scan, multiple disease simultaneous diagnosis" is expected to significantly enhance the competitiveness and added value of the company's imaging center services [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Jiangxi Rimag Group Co., Ltd. 江西一脈陽光集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2522） 自願公告 影禾醫脈發佈全球首個基座大模型驅動的AI輔助診斷產品 本公告由江西一脈陽光集團股份有限公司（「本公司」，連同其附屬公司統稱為「本 集團」）董事（「董事」）會（「董事會」）自願作出。 董事會欣然宣佈，2025年10月16日，由本集團參股孵化的人工智能公司上海影 禾醫脈智能科技有限公司（「影禾醫脈」），正式發佈全球首個基於醫學影像基座大 模型「影禾覓芽®」研發的AIR（路徑級AI輔助診斷產品）——胸部CT平掃輔助診斷 AIR（「AIR產品」）。AIR產品標誌着醫學影像AI正式從「單病種小模型」的1.0時 代，邁入「基座大模型驅動」的2.0時代，具備全病灶、全病種、多器官協同診斷 能力，是醫學影像智能診斷領域的一項里程碑式突破。 AIR產品不僅 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 江西一脈陽光集團股份有限公司 第 1 頁 共 10 頁 v 1.1.1 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02522 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 293,282,074 | | 846,000 | | 294,128,074 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 293,282,074 | | 846,000 | | 294,128,074 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請 ...